New horizons in hCG detection

A highly sensitive and specific sandwich enzyme immunoassay for detection of human chorionic gonadotropin in trophoblastic disease

A highly sensitive and specific two-site enzyme immunoassay (EIA) kit for human chorionic gonadotropin (hCG) has been examined and applied to the detection of hormones in the serum of normal individuals and patients with trophoblastic disease. This EIA uses a solid phase coupled antibody to the unique COOH terminal peptide region of the hCG beta-subunit (beta-CTP) and an enzyme conjugated monoclonal antibody to the hCG beta-subunit. The overnight 2 step assay measured as little as 0.2 mIU/ml serum without hLH interference and a rapid one step assay was newly developed in our laboratory. Assays of serum from normal men and nonpregnant women of reproductive age indicated that most individuals did not have detectable serum levels of hCG immunoreactivity, although a minority had minute amounts. In contrast, women with non-functional ovaries had detectable levels of hCG immunoreactivity with a mean value of 0.86 mIU/ml serum. The extremely high sensitivity and specificity of the EIA in detecting hCG provides substantial advantages for the detection of early pregnancy and for monitoring trophoblastic tumors.

Molecular forms of human chorionic gonadotropin in choriocarcinoma serum and urine

The molecular forms of human chorionic gonadotropin (hCG) were assessed in parallel serum and urine samples from a choriocarcinoma patient by gel chromatography, isoelectric focusing, and Western blot analysis. There were significant qualitative differences in the molecular forms of hCG between the serum and the urine. The serum hCG had a greater molecular weight and a stronger acidic charge than the urinary hCG. These results may be attributed to differences of sialic acid contents. Affinity chromatography using Ricinus communis agglutinin-conjugated Sepharose showed that the serum hCG was completely sialylated, while the urinary hCG was partially desialylated. In addition to the complete hCG molecule, two kinds of hCGbeta-related fragments were detected in the urine of the patient, but not in the serum. In the Western blot using anti-hCGbeta or anti-hCGbeta-CTP under reducing conditions, the urine presented a new band (CTP') with Mr 23,000 in addition to the beta-subunit, while the serum revealed a single band of the beta-subunit with or without a reducing reagent. The present data revealed striking qualitative differences in the molecular forms of hCG between serum and urine of a patient with choriocarcinoma.